Clinical trials
NSCLC (Advanced Non-small Cell Lung Cancer) clinical trials
Below are recruiting nsclc (advanced non-small cell lung cancer) clinical trials, each written for real people, not researchers. We’re tracking 538 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06846762Recruiting
DNA/RNA co-testing for advanced lung cancer that has stopped responding to first treatment
This study is for people with advanced non-small cell lung cancer whose tumors do not have certain genetic changes (called driver mutations) and whose first treatment did not work well or caused bad side effects within 6 months. The researchers want to use a special test (DNA/RNA-NGS) to look for hidden genetic alterations that might explain why the cancer didn't respond.
Shanghai, Shanghai MunicipalityAges Any age - NCT06849167RecruitingPhase 2
Immunotherapy with low-dose chemoradiation for advanced lung cancer
This trial tests combining immunotherapy with a shorter course of chemoradiation for locally advanced non-small cell lung cancer that hasn't spread. It aims to see if this approach is more effective and tolerable than standard treatment.
BeijingAges 18–70 - NCT06855771RecruitingPhase 2
Study of an oral drug for MTAP-deleted advanced lung cancer
This study tests an experimental oral medication (navlimetostat) for people with advanced lung cancer whose tumors have a specific genetic change called an MTAP deletion. It’s for those whose cancer has progressed after earlier treatments.
Anchorage, AlaskaAges 18 years+ - NCT06861543RecruitingPhase 1
TMT101 for advanced pancreatic or lung cancer
This trial tests a new drug called TMT101 for people with advanced pancreatic cancer or non-small cell lung cancer who have already tried other treatments. The goal is to see if TMT101 is safe and works against the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06868485RecruitingPhase 2
Study of WSD0922-FU for advanced lung cancer with C797S mutation
This trial tests a new drug, WSD0922-FU, for people with advanced non-small cell lung cancer that has a specific genetic change called C797S. It is for those whose cancer has gotten worse after treatment with osimertinib.
Oxnard, CaliforniaAges 18 years+ - NCT06895031RecruitingPhase 2
JYP0015 for advanced solid tumors with RAS mutations
This trial tests a new drug called JYP0015 for people with advanced solid tumors that have a specific change in the RAS gene. It aims to see if the drug can help when other treatments have stopped working or caused too many side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT06896422RecruitingPhase 1
Testing glutathione with immunotherapy and chemo for lung cancer
This trial tests adding a supplement called glutathione to the usual immunotherapy (anti-PD-1) plus chemotherapy for advanced non-small cell lung cancer that has stopped responding to first treatment. It aims to see if this combination works better at shrinking tumors.
Zhengzhou, HenanAges 18 years+ - NCT06896890RecruitingPhase 1/Phase 2
Inhaled cisplatin for stage IV lung cancer
This trial tests a new way to give the chemotherapy drug cisplatin—as a dry powder you inhale—for people with stage IV non-small cell lung cancer who have not yet started treatment. The goal is to see if this inhaled form is safe and effective when added to standard immunotherapy or chemotherapy.
BrusselsAges 18 years+ - NCT06902272RecruitingPhase 2
Blood test to predict chemo-immunotherapy response in lung cancer
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
Miami, FloridaAges 18 years+ - NCT06907615RecruitingPhase 2
Study of HLX43 for advanced non-small cell lung cancer
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT06908304RecruitingPhase 3
Study of THIO + Cemiplimab vs Chemo for Advanced Lung Cancer
This trial tests a new combination of drugs (THIO and cemiplimab) against standard chemotherapy for people with advanced non-small cell lung cancer who have already tried two prior treatments including immunotherapy and platinum chemo. The goal is to see if the combination helps control the cancer better.
PoznanAges 18 years+ - NCT06908993RecruitingPhase 3
Tepotinib vs standard care for MET-mutated lung cancer
This trial tests a targeted pill called tepotinib against standard treatments for advanced lung cancer with a specific MET gene change. It is for people whose cancer has progressed after at least one prior therapy.
BesançonAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
Los Angeles, CaliforniaAges 18 years+ - NCT06918132RecruitingPhase 2
Cemiplimab and Fianlimab before lung cancer surgery
This trial tests whether two immunotherapy drugs (cemiplimab and fianlimab) given before surgery can help treat stage IB to IIIB non-small cell lung cancer. You must have a PD-L1 level of at least 1% and your surgeon must think the tumor can be fully removed.
Rochester, MinnesotaAges 18 years+ - NCT06923618Recruiting
Lung Cancer and Aging in Older Adults
This trial looks at aging-related changes in older adults (70+) with early-stage lung cancer who are planning to have surgery. The goal is to better understand how these changes might affect recovery and outcomes, which could help improve care for future patients.
Créteil, Île-de-France RegionAges 70 years+ - NCT06928389RecruitingPhase 3
Ivonescimab plus docetaxel for advanced lung cancer
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06929936RecruitingPhase 2
Trilaciclib plus docetaxel for advanced lung cancer (second-line+)
This trial tests a new drug combination (trilaciclib plus docetaxel) for people with advanced lung cancer (NSCLC) whose cancer has progressed after at least one prior treatment. The goal is to see if adding trilaciclib helps the chemotherapy work better with fewer side effects.
Xiamen, FujianAges 18 years+ - NCT06930794RecruitingPhase 3
Study of Vebreltinib Plus Chemo for MET-Positive Lung Cancer
This trial tests a targeted drug (Vebreltinib) combined with standard chemotherapy in people with a specific type of advanced non-squamous lung cancer that has a MET gene change (amplification or overexpression). The goal is to see if this combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06934343Recruiting
Personalized therapy for advanced lung cancer using data
This trial uses real-world data to study how to personalize treatment for advanced non-small cell lung cancer. It looks at medical records from 2011 to 2024 to find the best therapy approaches.
Salt Lake City, UtahAges Any age - NCT06939127RecruitingPhase 2
Cold therapy, immunotherapy, and chemo before and after lung cancer surgery
This trial tests a treatment that uses extreme cold (cryoablation) along with immunotherapy (tislelizumab) and chemotherapy before and after surgery for people with early-stage lung cancer that can be removed. The goal is to see if this combination helps prevent the cancer from coming back.
TianjinAges 18–75 - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06943820RecruitingPhase 1/Phase 2
AK129 combination therapy for advanced solid tumors
This trial tests a new combination of drugs (including AK129) for people with advanced solid tumors, specifically lung cancer, head and neck cancer, or colorectal cancer. It is for those who have already tried a platinum chemo and a PD-1/PD-L1 drug but their cancer got worse.
Shenyang, LiaoningAges 18–75 - NCT06946927RecruitingPhase 1
Study of JMKX001899 with other drugs for advanced KRAS G12C lung cancer
This trial tests a new targeted therapy, JMKX001899, combined with other treatments for advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It aims to see if this combination can help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT06951646RecruitingPhase 2
Personalized treatment for advanced lung cancer with long response to first-line therapy
This trial tests a combination of ivonescimab and docetaxel for people with advanced non-small cell lung cancer who have had a long response (11-15 months without the cancer getting worse) to first-line immunotherapy. The goal is to see if adjusting treatment based on ctDNA-MRD levels can improve outcomes.
ChangshaAges 18–75
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nsclc (advanced non-small cell lung cancer)?
- Yes. Clin2 currently lists 538 recruiting nsclc (advanced non-small cell lung cancer) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nsclc (advanced non-small cell lung cancer) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nsclc (advanced non-small cell lung cancer) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Advanced Non-squamous Non-small-cell Lung Cancer
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.